Status:

COMPLETED

Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy

Lead Sponsor:

Braintree Laboratories

Conditions:

Colonoscopy

Eligibility:

All Genders

12-17 years

Phase:

PHASE2

Brief Summary

The purpose o this study is to evaluate the safety, tolerance and efficacy of BLI800 as a bowel preparation prior to colonoscopy in pediatric patients.

Eligibility Criteria

Inclusion

  • Key
  • Male or female between the ages of 12 to 17
  • Weight more than 40kg
  • Undergoing colonoscopy for routinely accepted indications
  • If female, and of child-bearing potential, subject must use an acceptable form of birth control or remain abstinent for the duration of the study.
  • Negative pregnancy test at screening, if applicable
  • In the Investigator's judgment, caregiver is mentally competent to provide informed consent for their child to participate in the study.

Exclusion

  • Subjects with known or suspected ileus, impaction, severe ulcerative colitis, acute peritonitis, gastrointestinal obstruction, gastric retention (gastroparesis), bowel perforation, toxic colitis or megacolon.
  • Subjects who had previous significant gastrointestinal surgeries.
  • Subjects with increased risk of bowel perforation, including connective tissue disorders, toxic dilation of the bowel or recent bowel surgery.
  • Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results
  • Subjects with bleeding disorders and/or impaired platelet function, or neutropenia.
  • Subjects with a prior history of renal, liver or cardiac insufficiency
  • Subjects required to take any other oral medication within 3 hours of dosing until completion of both doses.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects with tendency for nausea and/or vomiting, or that have known swallowing disorders.
  • Subjects for whom intake of substances is likely to affect gastrointestinal motility or urinary flow rate.
  • Subjects undergoing colonoscopy for foreign body removal and/or decompression.

Key Trial Info

Start Date :

June 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2015

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT02189850

Start Date

June 1 2014

End Date

January 1 2015

Last Update

March 15 2021

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Arkansas Children's Hospital Research Institute

Little Rock, Arkansas, United States

2

Children's Center for Digestive Health Care

Atlanta, Georgia, United States

3

Delta Research Partners

Bastrop, Louisiana, United States

4

Gastrointestinal Associates

Jackson, Mississippi, United States